Castle Biosciences (CSTL) Change in Account Payables (2018 - 2026)

Castle Biosciences has reported Change in Account Payables for 9 years, with the latest figure at -$2.3 million in Q2 2026.

• Quarterly Change in Account Payables fell 314.8% year-over-year to -$2.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.3 million (up 320.23% YoY) and the FY2025 annual result came in at $3.1 million, up 170.4% from the prior year.
• Change in Account Payables declined to -$2.3 million in Q2 2026 per CSTL's latest filing, from $3.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.9 million in Q1 2023 and troughed at -$2.3 million in Q2 2026.
• A 5-year average of $326722.2 and a median of $49000.0 in 2022 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 1983.42% in 2023, down 817.39% in 2023.
• Over 5 years, Change in Account Payables stood at -$1.6 million in 2022, then jumped by 291.61% to $3.0 million in 2023, then plunged by 118.91% to -$570000.0 in 2024, then soared by 97.02% to -$17000.0 in 2025, then slumped by 13470.59% to -$2.3 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$2.3 million, $3.2 million, and -$17000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.